1. Home
  2. BOC vs LCTX Comparison

BOC vs LCTX Comparison

Compare BOC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Omaha Corporation

BOC

Boston Omaha Corporation

HOLD

Current Price

$13.30

Market Cap

377.5M

Sector

N/A

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

388.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOC
LCTX
Founded
2009
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.5M
388.6M
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
BOC
LCTX
Price
$13.30
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
271.2K
1.2M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$114,376,348.00
$14,556,000.00
Revenue This Year
$5.79
$109.40
Revenue Next Year
$4.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.64
53.24
52 Week Low
$10.52
$0.65
52 Week High
$14.50
$2.09

Technical Indicators

Market Signals
Indicator
BOC
LCTX
Relative Strength Index (RSI) 60.11 34.20
Support Level $11.95 $1.14
Resistance Level $13.93 $1.31
Average True Range (ATR) 0.55 0.07
MACD 0.16 0.00
Stochastic Oscillator 83.69 5.71

Price Performance

Historical Comparison
BOC
LCTX

About BOC Boston Omaha Corporation

Boston Omaha Corp is a diversified holding company engaged in outdoor billboard advertising, broadband services, surety insurance, and related brokerage activities, and asset management. The company generates revenue mainly from leasing advertising space on billboards, providing broadband internet services, and earning premiums and commissions from its insurance operations. In addition, it holds minority equity investments in various businesses, including real estate-related and other industries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: